Outcome Capital argues that the orthopedic segment, and ortho in particular, remains highly attractive, as it offers investors stability, healthy multiples, and opportunities for innovation.
Published in MedTech Strategist
Author: Wendy Diller
Abstract:
Investors and entrepreneurs in recent years have gravitated away from orthopedics and medtech in general, toward splashier, hyper-growth subsectors of the life sciences, such as biotech and digital health. Outcome Capital argues that the industry—and ortho in particular—remains highly attractive, as it offers investors and entrepreneurs stability, healthy multiples, and opportunities for innovation.
The collaboration will allow the partners to globally expand financial advisory services and cross-border transactions for life sciences and biopharmaceutical client companies Boston & Shanghai – September 14, 2023. Outcome Capital, a specialized life science advisory and investment banking firm, and YAFO Capital, a Shanghai-based boutique investment banking and advisory firm, announced that the companies […]
Read MoreOutcome Capital Life Science Market Pulse August 2023 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?